Literature DB >> 27000234

HLA-DRB1*14 and DQB1*05 are associated with Japanese anti-MuSK antibody-positive myasthenia gravis patients.

Tetsuya Kanai1, Akiyuki Uzawa2, Naoki Kawaguchi3, Tateo Sakamaki4, Yasumasa Yoshiyama5, Keiichi Himuro1, Fumiko Oda1, Satoshi Kuwabara1.   

Abstract

BACKGROUND: Myasthenia gravis (MG) is an autoimmune disorder presumed to be associated with genetic susceptibility. This study aims to determine whether HLA is associated with MG in Japanese patients.
METHODS: We included 58 MG patients with anti-acetylcholine receptor antibody (AChR+MG) and 14 MG patients with muscle-specific receptor tyrosine kinase (MuSK+MG) and determined HLA-A, B, DRB1 and -DQB1 alleles using polymerase chain reaction with sequence-specific oligonucleotide and primers. AChR+MG was classified into the three subgroups: early-onset MG (EOMG; n=11), late-onset MG (LOMG; n=20), and thymoma-associated MG (n=27). Healthy volunteers (n=100) served as controls.
RESULTS: A significant positive association was observed between MuSK+MG with the DRB1*14 [57.1%, MuSK+MG vs. 18.0%, healthy controls (HC); odds ratio (OR): 6.1] and DQB1*05 [78.6%, MuSK+MG vs. 30.0%, HC; odds ratio (OR): 8.5]. We found a negative association between LOMG and DQB1*04 [5.0%, LOMG vs. 37.0%, HC; OR: 0.09]. There was no association between other MG subgroups and HLA alleles.
CONCLUSION: HLA-DRB1*14 and DQB1*05 were associated with MuSK+MG, therefore these alleles may play important roles in developing MuSK+MG across the races.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-acetylcholine receptor; HLA-DQB1*05; HLA-DRB1*14; Human leukocyte antigen; Muscle-specific receptor tyrosine kinase; Myasthenia gravis

Mesh:

Substances:

Year:  2016        PMID: 27000234     DOI: 10.1016/j.jns.2016.02.031

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

Review 1.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

2.  Relation of HLA-DRB1 to IgG4 autoantibody and cytokine production in muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG).

Authors:  M Çebi; H Durmuş; V Yılmaz; S P Yentür; F Aysal; P Oflazer; Y Parman; F Deymeer; G Saruhan-Direskeneli
Journal:  Clin Exp Immunol       Date:  2019-04-12       Impact factor: 4.330

3.  Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms.

Authors:  Yu Hong; Geir Olve Skeie; Paraskevi Zisimopoulou; Katerina Karagiorgou; Socrates J Tzartos; Xiang Gao; Yao-Xian Yue; Fredrik Romi; Xu Zhang; Hai-Feng Li; Nils Erik Gilhus
Journal:  J Neurol       Date:  2017-03-31       Impact factor: 4.849

4.  A systematic review and meta-analysis of HLA class II associations in patients with IgG4 autoimmunity.

Authors:  Anja Panhuber; Giovanni Lamorte; Veronica Bruno; Hakan Cetin; Wolfgang Bauer; Romana Höftberger; Astrid C Erber; Florian Frommlet; Inga Koneczny
Journal:  Sci Rep       Date:  2022-06-02       Impact factor: 4.996

Review 5.  Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica.

Authors:  Zhen Wang; Yaping Yan
Journal:  Front Immunol       Date:  2017-12-12       Impact factor: 7.561

Review 6.  Associations between HLA and autoimmune neurological diseases with autoantibodies.

Authors:  Sergio Muñiz-Castrillo; Alberto Vogrig; Jérôme Honnorat
Journal:  Auto Immun Highlights       Date:  2020-01-22

Review 7.  Common Denominators in the Immunobiology of IgG4 Autoimmune Diseases: What Do Glomerulonephritis, Pemphigus Vulgaris, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura and Autoimmune Encephalitis Have in Common?

Authors:  Inga Koneczny; Vuslat Yilmaz; Konstantinos Lazaridis; John Tzartos; Tobias L Lenz; Socrates Tzartos; Erdem Tüzün; Frank Leypoldt
Journal:  Front Immunol       Date:  2021-01-29       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.